Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas.

Yoon SS, Duda DG, Karl DL, Kim TM, Kambadakone AR, Chen YL, Rothrock C, Rosenberg AE, Nielsen GP, Kirsch DG, Choy E, Harmon DC, Hornicek FJ, Dreyfuss J, Ancukiewicz M, Sahani DV, Park PJ, Jain RK, Delaney TF.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1081-90. doi: 10.1016/j.ijrobp.2010.07.024.

2.
3.

[Management of soft tissue sarcomas in first isolated local recurrence: a retrospective study of 83 cases].

Moureau-Zabotto L, Thomas L, Bui BN, Chevreau C, Stockle E, Martel P, Bonneviale P, Marques B, Coindre JM, Kantor G, Matsuda T, Delannes M.

Cancer Radiother. 2004 Oct;8(5):279-87. French.

PMID:
15561593
4.

Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas.

Eilber FC, Rosen G, Eckardt J, Forscher C, Nelson SD, Selch M, Dorey F, Eilber FR.

J Clin Oncol. 2001 Jul 1;19(13):3203-9.

PMID:
11432887
5.

A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.

Haas RL, Gelderblom H, Sleijfer S, van Boven HH, Scholten A, Dewit L, Borst G, van der Hage J, Kerst JM, Nout RA, Hartgrink HH, de Pree I, Verhoef C, Steeghs N, van Coevorden F.

Acta Oncol. 2015;54(8):1195-201. doi: 10.3109/0284186X.2015.1037404.

PMID:
25920360
6.

Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial.

Roeder F, Lehner B, Schmitt T, Kasper B, Egerer G, Sedlaczek O, GrĂ¼llich C, Mechtersheimer G, Wuchter P, Hensley FW, Huber PE, Debus J, Bischof M.

BMC Cancer. 2014 May 20;14:350. doi: 10.1186/1471-2407-14-350.

7.

Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity.

Canter RJ, Borys D, Olusanya A, Li CS, Lee LY, Boutin RD, Christensen SD, Tamurian RM, Monjazeb AM.

Ann Surg Oncol. 2014 May;21(5):1616-23. doi: 10.1245/s10434-014-3543-7.

8.

Response assessment to neoadjuvant therapy in soft tissue sarcomas: using CT texture analysis in comparison to tumor size, density, and perfusion.

Tian F, Hayano K, Kambadakone AR, Sahani DV.

Abdom Imaging. 2015 Aug;40(6):1705-12. doi: 10.1007/s00261-014-0318-3.

PMID:
25526682
9.

Influence of site on the therapeutic ratio of adjuvant radiotherapy in soft-tissue sarcoma of the extremity.

Alektiar KM, Brennan MF, Singer S.

Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):202-8.

PMID:
16111590
10.

Prognostic value of necrosis after neoadjuvant therapy for soft tissue sarcoma.

Vaynrub M, Taheri N, Ahlmann ER, Yao C, Fedenko AN, Allison DC, Chawla SP, Menendez LR.

J Surg Oncol. 2015 Feb;111(2):152-7. doi: 10.1002/jso.23775.

PMID:
25175933
11.

Radiographic and histologic response to neoadjuvant radiotherapy in patients with soft tissue sarcoma.

Canter RJ, Martinez SR, Tamurian RM, Wilton M, Li CS, Ryu J, Mak W, Monsky WL, Borys D.

Ann Surg Oncol. 2010 Oct;17(10):2578-84. doi: 10.1245/s10434-010-1156-3.

12.

Predictors for major wound complications following preoperative radiotherapy and surgery for soft-tissue sarcoma of the extremities and trunk: importance of tumor proximity to skin surface.

Baldini EH, Lapidus MR, Wang Q, Manola J, Orgill DP, Pomahac B, Marcus KJ, Bertagnolli MM, Devlin PM, George S, Abraham J, Ferrone ML, Ready JE, Raut CP.

Ann Surg Oncol. 2013 May;20(5):1494-9. doi: 10.1245/s10434-012-2797-1.

PMID:
23242820
13.

High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality.

Eilber FC, Rosen G, Nelson SD, Selch M, Dorey F, Eckardt J, Eilber FR.

Ann Surg. 2003 Feb;237(2):218-26.

14.

Combined radiation therapy and sunitinib for preoperative treatment of soft tissue sarcoma.

Jakob J, Simeonova A, Kasper B, Ronellenfitsch U, Wenz F, Hohenberger P.

Ann Surg Oncol. 2015 Sep;22(9):2839-45. doi: 10.1245/s10434-015-4680-3.

PMID:
26085221
15.

Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy.

Mullen JT, Hornicek FJ, Harmon DC, Raskin KA, Chen YL, Szymonifka J, Yeap BY, Choy E, DeLaney TF, Nielsen GP.

Cancer. 2014 Dec 1;120(23):3676-82. doi: 10.1002/cncr.28945.

16.

Neoadjuvant chemoradiation therapy for soft tissue sarcomas of the extremities.

Aguiar Junior S, Ferreira Fde O, Rossi BM, Santos EM, Salvajoli JV, Lopes A.

Clinics (Sao Paulo). 2009;64(11):1059-64. doi: 10.1590/S1807-59322009001100005.

17.

Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.

Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK.

J Clin Oncol. 2009 Jun 20;27(18):3020-6. doi: 10.1200/JCO.2008.21.1771.

18.

Antiangiogenic and radiation therapy: early effects on in vivo computed tomography perfusion parameters in human colon cancer xenografts in mice.

Ren Y, Fleischmann D, Foygel K, Molvin L, Lutz AM, Koong AC, Jeffrey RB, Tian L, Willmann JK.

Invest Radiol. 2012 Jan;47(1):25-32. doi: 10.1097/RLI.0b013e31823a82f6.

19.

Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer.

Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, Wolff RA, Krishnan S, Hamilton S, Janjan NA, Maru DM, Ellis LM, Rodriguez-Bigas MA.

Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):824-30. doi: 10.1016/j.ijrobp.2009.02.037.

PMID:
19464823
20.

Modified staging system for extremity soft tissue sarcomas.

Ramanathan RC, A'Hern R, Fisher C, Thomas JM.

Ann Surg Oncol. 1999 Jan-Feb;6(1):57-69.

PMID:
10030416
Items per page

Supplemental Content

Support Center